RESEARCH TRIANGLE PARK, N.C., July 31, 2018 /PRNewswire/ -- Marken announced today the opening of a new branch located in Melbourne. The new location joins Sydney and Brisbane as the third Australian hub and solidifies the company's position as the leader in Australia for clinical trial supply chain solutions.
Continuing and growing client demand for Marken's services precipitated the planned addition of these facilities across Australia. The opening of this new facility provides Marken Australia with the strongest set of locations and services across the country to offer to clients. The opening also reinforces the company's commitment to the growing biotech and medical research industries in the State of Victoria.
The clinical trial market in Australia continues to expand with over 5.2 million people participating in 10,000 Australian clinical trials over a 10 year period. More than $1 billion is invested in Australian clinical trials each year by both government and industry. Australia is in the top five bio-economies globally, and Australia's biotechnology and life sciences sector continues to show healthy performance for the fifth consecutive year. The industry is expected to continue growing, reaching close to $8B in revenue over the current year.
The Melbourne location is only 7 kilometers from Melbourne International Airport and provides two levels of offices, warehouse and mezzanine storage with easy access for larger vehicles delivery and pickups. Temperature controlled rooms and equipment ensure product integrity from pick up to final delivery including a walk in 2-8 C refrigerator, a controlled ambient room of 15-25 degrees plus two -20C freezers and a -30C freezer.
Michael Culme-Seymour, VP Asia Pacific (APAC) Region, said this about the expansion, "Our new Operations team along with a fleet of Marken drivers have quickly jump started the service and are already serving the growing client base in that area. This new location will strengthen our emphasis on quality customer service and provide us the opportunity to reach even more patients and with the fastest response times possible."
The Original Article: